We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-9.95%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$521M
AUM Growth
-$149M
(-22%)
Cap. Flow
-$67.8M
Cap. Flow
% of AUM
-13.02%
Top 10 Holdings %
Top 10 Hldgs %
35.83%
Holding
77
New
12
Increased
14
Reduced
37
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$13M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$11.3M |
| 3 |
PPD
PPD, Inc. Common Stock
PPD
|
+$11.2M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$10.2M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$14.5M |
| 2 |
Teladoc Health
TDOC
|
+$14.3M |
| 3 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$11.8M |
| 4 |
STML
Stemline Therapeutics, Inc.
STML
|
+$10.9M |
| 5 |
Tandem Diabetes Care
TNDM
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.94% |
| 2 | Industrials | 4.93% |
| 3 | Technology | 1.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Aprea Therapeutics
APRE
$7.83M
| $51.1M | 9.81% |
73,517
| – | – |
|
|
2
Teladoc Health
TDOC
$1.58B
| $27.3M | 5.23% |
175,875
-122,817
| -41% | -$14.3M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.5B
| $15.5M | 2.98% |
184,011
-39,890
| -18% | -$3.44M |
|
4
Boston Scientific
BSX
$65.8B
| $15.5M | 2.97% |
474,334
-44,042
| -8% | -$1.72M |
|
|
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
| $14.4M | 2.76% |
1,557,961
-502,000
| -24% | -$4.77M |
|
6
PTC Therapeutics
PTCT
$6.37B
| $13.3M | 2.56% |
298,844
-29,894
| -9% | -$1.51M |
|
|
7
Tandem Diabetes Care
TNDM
$1.17B
| $12.6M | 2.41% |
195,264
-146,450
| -43% | -$10.3M |
|
|
8
Sarepta Therapeutics
SRPT
$1.66B
| $12.4M | 2.38% |
126,759
+69,999
| +123% | +$8M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $12.3M | 2.37% |
107,000
+92,000
| +613% | +$10.2M |
|
|
10
Exelixis
EXEL
$13.9B
| $12.2M | 2.34% |
+708,090
| New | +$13M |
|
|
HRC
11
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $11.8M | 2.26% |
117,099
-5,500
| -4% | -$570K |
|
|
KYNB
12
Kyntra Bio
KYNB
$28.5M
| $11.7M | 2.24% |
13,420
-1,252
| -9% | -$1.24M |
|
13
Biogen
BIIB
$29.9B
| $11.4M | 2.19% |
35,992
+3,450
| +11% | +$1.05M |
|
14
Bristol-Myers Squibb
BMY
$127B
| $10.7M | 2.05% |
191,974
-27,500
| -13% | -$1.68M |
|
|
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $10.7M | 2.05% |
74,009
-6,641
| -8% | -$1.28M |
|
|
IMMU
16
DELISTED
Immunomedics Inc
IMMU
| $10.3M | 1.97% |
762,123
+70,000
| +10% | +$1.18M |
|
|
APLS
17
DELISTED
Apellis Pharmaceuticals
APLS
| $10.2M | 1.95% |
378,923
-76,470
| -17% | -$2.71M |
|
18
Acadia Pharmaceuticals
ACAD
$4.25B
| $10M | 1.93% |
237,450
+93,000
| +64% | +$3.83M |
|
|
TRHC
19
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $9.21M | 1.77% |
176,156
-31,026
| -15% | -$1.68M |
|
|
GBT
20
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.06M | 1.74% |
177,294
+2,700
| +2% | +$181K |
|
21
Assembly Biosciences
ASMB
$506M
| $9.04M | 1.74% |
50,791
-6,934
| -12% | -$1.49M |
|
22
AtriCure
ATRC
$1.77B
| $8.62M | 1.65% |
256,606
-277,150
| -52% | -$9.96M |
|
23
Alnylam Pharmaceuticals
ALNY
$36.3B
| $8.47M | 1.63% |
77,800
-9,800
| -11% | -$1.13M |
|
|
DCPH
24
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $8.4M | 1.61% |
+204,059
| New | +$11.3M |
|
|
RCM
25
DELISTED
R1 RCM Inc. Common Stock
RCM
| $8.39M | 1.61% |
923,573
-235,500
| -20% | -$2.83M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q1 2020 Portfolio in Review
As of Q1 2020, Sectoral Asset Management held 77 positions worth $521M, down 22% from $670M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sectoral Asset Management withdrew a net $67.8M in Q1 2020, closing 12 positions and reducing 37 holdings. Its most notable exit was Portola Pharmaceuticals, Inc., an estimated $14.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Industrials and Technology.
Against the trend, Sectoral Asset Management opened a new position in Exelixis worth $12.2M.
- Sectoral Asset Management's largest Q1 2020 buy was Exelixis: 708,090 shares worth $12.2M.
- Sectoral Asset Management added most to Seagen Inc. Common Stock in Q1 2020, an estimated $10.2M increase.
- Sectoral Asset Management's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $14.3M.
- Sectoral Asset Management fully exited Portola Pharmaceuticals, Inc. in Q1 2020, selling an estimated $14.5M.
- Sectoral Asset Management's ten largest holdings make up 36% of its $521M portfolio in Q1 2020.
- Sectoral Asset Management opened 12 new positions and closed 12 in Q1 2020.
- Sectoral Asset Management's portfolio value fell 22% quarter-over-quarter to $521M.
Based on Sectoral Asset Management's 13F filing for Q1 2020, filed 13 May 2020.